mRNA

mRNA is a new class of therapeutics designed to instruct patients’ own cells to produce a protein that can treat, cure or prevent diseases. mRNA therapeutics are being developed as vaccines against infectious diseases, as cancer immunotherapy, and as protein replacement therapy for rare diseases.

Building on its considerable experience in the analysis of complex innovative drugs, Quality Assistance is continuously advancing ways to support the development of your mRNA-based therapeutics and expanding its related machinery and equipment.

Analytical services for mRNA-based therapeutics:

  • General quality
  • Identity
  • Quantity
  • Purity & Integrity
  • Potency
  • Process related impurities
  • Nano-delivery system
  • Packaging

Your reliable analytical partner:

  • Thorough regulatory, scientific and technical monitoring and skilled teams
  • Commitment to providing the highest quality services and generating reliable data in order to enable our clients to consistently market safe products.
  • Compliance with all applicable EMA, FDA and ICH regulations
  • GMP, GLP, GCLP/GCP environment
GENERAL QUALITY
AppearanceVisual inspection
pH 
Osmolarity 
Extractable volume 
Particulate matterOptical microscopy / Light Obscuration / Imaging Particle Analysis
IDENTITY
Oligonucleotide mapping(U)HPLC (UV, MS)
SequenceRT-PCR, NGS
QUANTITY
Content (RNA concentration)UV spectroscopy / Slope Spectroscopy (SoloVPE) / Anion Exchange Chromatography (UV)
PURITY & INTEGRITY
Size SEC (UV, RI, MALLS) / cGE (LIF)
PurityIon-exchange chromatography (UV), IP-RP-(U)HPLC (UV)
5' Capping efficiency(U)HPLC (UV, MS)
3’ poly(A) tail length and percentage(U)HPLC (UV, MS)
Residual dsRNAELISA
POTENCY
Cell-based assays (in vitro expression)Different read-outs
PROCESS RELATED IMPURITIES
Residual DNA templateRT-qPCR
Process contaminantsCE / GC (FID, MS) / (U)HPLC (UV, MS, Fluo, CAD, Conductimetry) / ELISA / ICP (OES, MS)
Residual solventsHS-GC (FID, MS) / (U)HPLC (UV, MS)
Elemental impuritiesICP (OES, MS)
MicrobiologyBioburden / Sterility (filtration, direct inoculation)
EndotoxinsLAL (kinetic, endpoint) / Monocyte Activation Test / Recombinant Factor C
NANODELIVERY SYSTEM
Size distributionDLS / A4F (UV, RI, MALLS)
Surface charge / zeta potentialM3-PALS (Zetasizer)
RNA contentFluorescence-based assay
Encapsulation efficiencyFluorescence-based assay
Lipid analysis (identity, content & impurities)(U)HPLC (CAD, MS)
PACKAGING
LeachablesGC (FID, ECD, MS) / ICP (OES, MS) / (U)HPLC (UV, ELSD, CAD, MS)
Container Closure System IntegrityBubbling / Dye ingress (methylene blue, fluorescence) / Microbial ingress
Downloadfile
Fill out this form to download this resource

Complete this form and access this document in seconds.